ICER To Open Cost Effectiveness Models To Drug Firms During Review Process
Institute for Clinical and Economic Review launching pilot program that allows drug assessment models to be inspected, but not manipulated, by manufacturers.
You may also be interested in...
New Migraine Drugs May Not Be Cost Effective In Patients With Other Options, ICER Suggests
Draft cost effectiveness report released by the Institute for Clinical and Economic Review uses $8,500 annual cost for Aimovig and fremanezumab as a "placeholder" price.
Open-Source Rx Value Model Designed To Encourage 'More Productive' Discussions
Industry-funded Open-Source Value Project aims to disseminate tools to the marketplace for customized value assessments, as opposed to offering a specific estimate of value for pricing and coverage decisions.
Keytruda, Opdivo May Be Only Part B Drugs Chosen For Medicare Negotiation In First Applicable Year
In general, more Part D drugs will be eligible than Part B drugs in the early years of the program because Part D drugs have higher levels of spending and so will dominate the list of candidates. A new report sizes up the drugs that would qualify for Medicare Price negotiation in 2026-2028.